Content
FDA approved for more than 25 years
In 2022, the U.S. Food and Drug Administration (FDA) approved the first JAK inhibitor for alopecia. Could a JAK inhibitor be the right hair loss treatment option for you?
Short answer: It depends on the type of hair loss you’re experiencing.
Below, we discuss JAK inhibitors, how they target certain forms of hair loss, how they compare to conventional hair loss treatments like finasteride and minoxidil, and more.
Content
A JAK inhibitor (short for janus kinase inhibitor) is a relatively new treatment. This type of medication works by calming an overactive immune system, helping to limit symptoms of autoimmune diseases.
Several JAK inhibitors are available to treat rheumatoid arthritis, including
Tofacitinib (Xeljanz®)
Baricitinib (Olumiant®)
Upadacitinib (Rinvoq®)
Alopecia areata (AA) is an autoimmune disease where the immune system targets, attacks, and damages hair follicles, causing hair to shed.
Unlike male pattern baldness (androgenetic alopecia) — which can be measured using the Norwood scale — alopecia areata generally causes hair to fall out in small patches about the size of a quarter.
Alopecia areata can vary in severity. While many will experience small patches of hair loss limited to the scalp, others might face complete loss of facial and body hair known as alopecia universalis or alopecia totalis.
Baricitinib (Olumiant) has FDA approval to treat AA in adults with severe alopecia areata.
It’s the first FDA-approved JAK inhibitor for AA-related hair loss on the scalp and body. It works by blocking the janus kinase subtypes JAK1 and JAK2.
In a series of randomized, double-blind, placebo-controlled trials, people with alopecia areata experienced improvements in hair regrowth with baricitinib compared to a placebo.
The research also found that 4 milligrams (mg) of baricitinib — the highest dose used in the studies — led to more improvement in human hair follicle regrowth than the lower 2-milligram dose.
Baricitinib is currently the only JAK inhibitor approved by the FDA as a treatment for hair loss. But researchers have also studied other JAK inhibitors for alopecia, including ruxolitinib (Jakafi®).
A systematic review and meta-analysis found that oral JAK inhibitors generally deliver effective results. And while side effects were uncommon, typically mild, and manageable, adverse events did occur.
Oral tofacitinib and other oral JAK inhibitors like ritlecitinib (Pfizer’s Litfulo®, which blocks the subtype JAK3) may also help teens and kids dealing with alopecia areata and skin conditions like atopic dermatitis (eczema) and psoriasis.
Like other medications that get FDA approval, baricitinib went through a complex series of clinical trials and safety assessments to determine that it’s effective and safe for ongoing use in people with alopecia areata.
But as with any medication, JAK inhibition may cause side effects.
The most common side effects include:
Headaches
Skin issues, such as acne
Upper respiratory tract infections
Lower respiratory tract infections
Elevated liver enzyme levels
Urinary tract infections (UTIs)
Inflamed hair follicles (folliculitis)
Anemia (low red blood cells)
Low white blood cell count
High cholesterol levels
Genital yeast infections
Shingles (herpes zoster)
Abdominal pain
Weight gain
Fatigue
Additionally, you shouldn’t take baricitinib with the following medications:
Other JAK inhibitors
Biologic immunomodulators
Medications that suppress the immune system
It’s also important to note that JAK inhibitors have several black box warnings, the strongest type of warning from the FDA. So be sure to read the fine print before taking them and talk to your healthcare provider about any safety concerns.
If you have alopecia areata, your provider will go over potential side effects, drug interactions, and long-term safety before prescribing any type of JAK inhibitor. Together, you can weigh the possible risks and benefits of this medication for your particular situation.
For more insight, see our blog on what to avoid when you have alopecia areata.
Medications like finasteride and minoxidil are proven hair loss treatments.
Finasteride works by limiting dihydrotestosterone (DHT), a hormone that can cause hair follicles to miniaturize and shed. But since alopecia areata isn’t triggered by DHT, medications like finasteride aren’t effective at stopping this form of hair loss.
Available as a topical foam or liquid solution, minoxidil works by improving blood flow to your scalp to encourage scalp hair regrowth in men with receding hairlines, bald spots, or central scalp hair loss. One clinical study found that the medication produced noticeable regrowth of hair in patients with alopecia areata.
However, if you have alopecia areata, you’ll get the best results by combining minoxidil with other treatments.
Conventional hair loss treatment options — the kinds you might use if you notice a receding hairline or mild thinning — work well for male pattern baldness, but they aren’t the best remedies for alopecia areata.
If you have alopecia areata, using a JAK inhibitor such as baricitinib may help you avoid patchy hair loss and regrow hair you’ve lost as a result of the autoimmune condition.
JAK inhibitors are fairly new medications for hair loss. You may need to talk to a healthcare provider who specializes in the treatment of alopecia areata to access this type of medication.
You can ask your primary care provider for a dermatology referral, or schedule an appointment with a medical professional in your area who specializes in treating autoimmune hair loss.
There are a few things to keep in mind if you’re considering this type of medication for hair loss:
Not everyone experiences improvements with JAK inhibition. Research suggests that nearly two in every five people experience significant hair regrowth with Olumiant. In other words, it works in some cases, but not for everyone.
JAK inhibitors aren’t proven to treat male pattern baldness. This type of medication is only approved for severe alopecia areata, not the male pattern hair loss that can cause a receding hairline.
If you’re starting to develop a receding hairline, a bald patch at your crown, or other early signs of balding, you’ll get better results from treatments like finasteride and minoxidil.
We offer these medications as part of our range of hair loss treatments for men, following an online consultation with a healthcare provider who can determine if a prescription is appropriate.
Interested in learning more before you get started? Our guide to the best treatments for thinning hair covers how to limit shedding and maintain your hair as you get older, from medications to healthy habits and more.
Hims & Hers has strict sourcing guidelines to ensure our content is accurate and current. We rely on peer-reviewed studies, academic research institutions, and medical associations. We strive to use primary sources and refrain from using tertiary references. See a mistake? Let us know at [email protected]!
Dr. Knox Beasley is a board certified dermatologist specializing in hair loss. He completed his undergraduate studies at the United States Military Academy at West Point, NY, and subsequently attended medical school at Tulane University School of Medicine in New Orleans, LA.
Dr. Beasley first began doing telemedicine during his dermatology residency in 2013 with the military, helping to diagnose dermatologic conditions in soldiers all over the world.
Dr. Beasley is board certified by the American Board of Dermatology, and is a Fellow of the American Academy of Dermatology.
Originally from Nashville, TN, Dr. Beasley currently lives in North Carolina and enjoys spending time outdoors (with sunscreen of course) with his wife and two children in his spare time.
Bachelor of Science, Life Sciences. United States Military Academy.
Doctor of Medicine. Tulane University School of Medicine
Dermatology Residency. San Antonio Uniformed Services Health Education Consortium
Board Certified. American Board of Dermatology
Wilson, L. M., Beasley, K. J., Sorrells, T. C., & Johnson, V. V. (2017). Congenital neurocristic cutaneous hamartoma with poliosis: A case report. Journal of cutaneous pathology, 44(11), 974–977. https://onlinelibrary.wiley.com/doi/10.1111/cup.13027
Banta, J., Beasley, K., Kobayashi, T., & Rohena, L. (2016). Encephalocraniocutaneous lipomatosis (Haberland syndrome): A mild case with bilateral cutaneous and ocular involvement. JAAD case reports, 2(2), 150–152. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867906/
Patterson, A. T., Beasley, K. J., & Kobayashi, T. T. (2016). Fibroelastolytic papulosis: histopathologic confirmation of disease spectrum variants in a single case. Journal of cutaneous pathology, 43(2), 142–147. https://onlinelibrary.wiley.com/doi/10.1111/cup.12569
Beasley, K., Panach, K., & Dominguez, A. R. (2016). Disseminated Candida tropicalis presenting with Ecthyma-Gangrenosum-like Lesions. Dermatology online journal, 22(1), 13030/qt7vg4n68j. https://pubmed.ncbi.nlm.nih.gov/26990472/
Kimes, K., Beasley, K., & Dalton, S. R. (2015). Eruptive milia and comedones during treatment with dovitinib. Dermatology online journal, 21(9), 13030/qt8kw141mb. https://pubmed.ncbi.nlm.nih.gov/26437285/
Miladi, A., Thomas, B. C., Beasley, K., & Meyerle, J. (2015). Angioimmunoblastic t-cell lymphoma presenting as purpura fulminans. Cutis, 95(2), 113–115. https://pubmed.ncbi.nlm.nih.gov/25750965/
Beasley K, Dai JM, Brown P, Lenz B, Hivnor CM. (2013). Ablative Fractional Versus Nonablative Fractional Lasers – Where Are We and How Do We Compare Differing Products?. Curr Dermatol Rep, 2, 135–143. https://idp.springer.com/authorize?response_type=cookie&client_id=springerlink&redirect_uri=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs13671-013-0043-0
Siami P, Beasley K, Woolen S, Zahn J. (2012). A retrospective study evaluating the efficacy and tolerability of intra-abdominal once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer. UroToday Int J, June 5(3), art 26. https://www.urotoday.com/volume-5-2012/vol-5-issue-3/51132-a-retrospective-study-evaluating-the-efficacy-and-tolerability-of-intra-abdominal-once-yearly-histrelin-acetate-subcutaneous-implants-in-patients-with-advanced-prostate-cancer.html
Siami P, Beasley K. (2012). Dutasteride with As-Needed Tamsulosin in Men at Risk of Benign Prostate Hypertrophy Progression. UroToday Int J, Feb 5(1), art 93. https://www.urotoday.com/volume-5-2012/vol-5-issue-1/48691-dutasteride-with-as-needed-tamsulosin-in-men-at-risk-of-benign-prostatic-hypertrophy-progression.html